secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062109
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT Q3 2023 net loss narrows to $10.3M; cash $320M, runway into H1 2026; clinical progress across pipeline
--------------------------------------------------------------------------------

- Net loss of $10.3M versus $25.7M in Q3 2022; decrease primarily due to $20M upfront from Astellas License Agreement.
- Cash, cash equivalents and marketable securities $320M as of Sep 30, 2023, up from $218M at Dec 31, 2022; runway into first half of 2026.
- Completed enrollment of 4D-150 PRISM Phase 2 Dose Expansion for wet AMD nearly two quarters ahead of schedule; interim data expected early 2024.
- Received EMA PRIME designation for 4D-150; reached agreement with FDA on plan to lift clinical hold on 4D-310 for Fabry disease cardiomyopathy.
- R&D expenses rose to $25.1M from $18.9M driven by clinical trial progression and higher headcount; G&A expenses $9.1M versus $8.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017023062109/0000950170-23-062109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017023062109/fdmt-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer